Healthy Subjects, Pharmacodynamics of ASP7657, Pharmacokinetics of ASP7657
Conditions
Keywords
ASP7657, Pharmacokinetics, Pharmacodynamics, Healthy Subjects, First in man, Safety
Brief summary
The purpose of this study is to evaluate the safety and tolerability of single and multiple ascending oral doses of ASP7657 in healthy subjects.
Detailed description
Subjects are healthy males aged 18 to 55 years of age (inclusive) (Parts 1 and 2, young cohorts) or the subject is an elderly healthy male or female subject aged 65 years or more (Part 2, elderly cohort).
Interventions
DRUGASP7657
oral
DRUGPlacebo
oral
DRUGnaproxen
oral
Sponsors
Astellas Pharma Europe B.V.
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Subject has a body mass index (BMI) range of 18.5 to 30.0 kg/m2, inclusive. The subject weighs at least 50 kg \[screening\] * Subject agrees to undergo gastro-duodenoscopy (GDS) if needed (Part 1: in case of gastrointestinal (GI) complaints/positive fecal blood test; Part 2: all subjects)
Exclusion criteria
* Subject has known or suspected hypersensitivity to ASP7657 or naproxen, or any components of the formulation used * Subject has any of the liver function test above the upper limit of normal (ULN) * Subject has any clinically significant history of allergic conditions (including drug allergies, asthma, eczema, or anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) * Subject has any history or evidence of any clinically significant cardiovascular, GI, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease or malignancy * Subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection), or fungal (noncutaneous) infection within 1 week prior to day of admission * Subject has any clinically significant abnormality * Subject has a pulse \< 40 or \> 90 beats per minute (bpm); mean systolic blood pressure (SBP) \> 140 mmHg; mean diastolic blood pressure (DBP) \> 90 mmHg (measurements taken in triplicate after subject has been resting in supine position for 5 minutes; pulse will be measured automatically) at day -1. (For elderly subjects the following criteria apply: DBP \> 100 mmHg, SBP \> 160 mmHg \[day of admission\]) * Subject has a mean QT interval corrected for heart rate using Fridericia's formula (QTc(F)) of \> 430 ms (for males) and \> 450 ms (for females). * Subject uses any prescribed or nonprescribed drugs (including nonsteroidal anti-inflammatory drugs (NSAIDs), anti-coagulants, vitamins, natural and herbal remedies, e.g., St. John's wort) in the 2 weeks prior to first study drug administration, except for occasional use of paracetamol (up to 2 g/day) * Subject has a history of smoking more than 10 cigarettes (or equivalent amount of tobacco) per day within 3 months prior to admission to the clinical unit. * Subject has a history of drinking \> 21 units (males) or \> 14 units (females) of alcohol per week (1 unit = 10 g pure alcohol = 250 mL of beer \[5%\] or 35 mL of spirits \[35%\] or 100 mL of wine \[12%\]) within 3 months prior to admission to the clinical unit or the subject tests positive at screening or clinical admission for alcohol or drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, and opiates) * Subject uses any drugs of abuse within 3 months prior to admission to the clinical unit * Subject has significant blood loss, donated 1 unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to clinic admission * Subject uses any inducer of metabolism (e.g., barbiturates, rifampin) in the 3 months prior to admission to the clinical unit regularly * Subject has a positive serology test for hepatitis B surface antigen (HBsAg), anti-hepatitis A virus (HAV) (immunoglobulin \[Ig\]M), anti-hepatitis C virus (HCV) or anti-human immunodeficiency virus (HIV) 1+2 * Subject has a positive H.Pylori test at screening * Subject has a positive fecal blood test at screening * Subject participated in any interventional clinical study or has been treated with any investigational drugs within 90 days or 5 half-lives whichever is longer, prior to the initiation of screening * Subject is an employee of the Astellas Group or Clinical Research Organization involved in the study * Subject has a history of peptic ulceration or significant dyspepsia * Subject uses concomitant medication associated with peptic ulceration, or presence of other risk factors for peptic ulceration * Subject, if non-elderly, has endoscopic evidence of inflammation, ulceration, erosion, mucosal hemorrhage, or active bleeding in esophagus, stomach, pyloric channel or duodenum, and a mucosal grading scale score \> 2 for both stomach and duodenum at baseline visit (Part 2 healthy young male cohorts)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Part 1 and 2: Safety assessed by adverse events, vital signs, laboratory tests, electrocardiogram (ECGs), collagen and adenosine diphosphate (ADP)-induced platelet aggregation, and gastrointestinal (GI) safety assessments (Part 2 only) | Up to Day 20 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Part 1: Pharmacokinetics (PK) profile of ASP7657 after a single dose in plasma: AUCinf, AUClast, tlag, tmax, Cmax, t 1/2, Vz/F, CL/F | Day 1 | Area under the concentration-time curve (AUC) from the time of dosing extrapolated to time infinity (AUCinf), AUC from the time of dosing to the last measurable concentration (AUClast), time prior to the time corresponding to the first measurable (nonzero) concentration (tlag), time of maximum plasma concentration (tmax), maximum plasma concentration (Cmax), terminal elimination half-life (t ½), apparent volume of distribution during the terminal elimination phase after extravascular dosing (Vz/F), and apparent total systemic clearance after single or multiple extravascular dosing (CL/F) |
| Part 1: PK profile of ASP7657 in urine: Aelast, Aeinf, Aelast%, Aeinf%, CLr | Day 1 | Cumulative amount of drug excreted in urine from time of dosing up to the collection time of the last measurable concentration (Aelast), cumulative amount of drug excreted in urine from time of dosing extrapolated to time infinity (Aeinf), percent of drug dose excreted in urine from time of dosing up to the collection time of the last measurable concentration (Aelast%), percent of drug dose excreted in urine from time of dosing extrapolated to time infinity (Aeinf%), renal clearance (CLr) |
| Part 1: Pharmacodynamics (PD) profile of tumor necrosis factor alpha (TNF-α) in whole blood: maximum response (Rmax), area under the dose-response curve (AURC), and time to reach maximum response (tmax,R) | Day 1 | — |
| Part 1: PD in urine: Total urine volume over 24 hours | Day -1 and Day 1 | — |
| Part 2: PK of ASP7657 in plasma: concentration immediately prior to dosing at multiple dosing (Ctrough) | Days 2, 4, 6, 8, 10 and 12 | — |
| Part 2: PK profile of ASP7657 after last dose in plasma: AUC from the time of dosing to the start of the next dosing interval (AUCtau), tmax, Cmax, t ½, Vz/F, CL/F, Accumulation ration (Racc), peak-trough ratio (PTR) | Day 14 | — |
| PK profile of ASP7657 after last dose in urine: Aetau, (Aetau%), and CLr | Day 14 | Cumulative amount of drug excreted in urine from the time of dosing to the start of the next dosing interval (Aetau), percent of drug dose excreted in urine over the time interval between consecutive dosing (Aetau%) |
| Part 2: PD profile of plasma renin activity and aldosterone | Days -1, 7, and 14 | — |
| Part 2: PD of urine electrolytes: amount excreted over 24 hours (Ae24) | Days -1 and 14 | — |
| Part 2: PK profile of ASP7657 after first dose in plasma: tlag, tmax, Cmax and AUC from the time of dosing to 24 hours postdose (AUC24) | Day 1 | — |
Countries
United Kingdom
Outcome results
None listed